Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 3, Randomized-Controlled, Open-Label, Multi-Regional, International Study of Futibatinib (TAS-120) and Zimberelimab (AB122) in Combination With Gemcitabine Plus Cisplatin Versus Durvalumab or Pembrolizumab in Combination With Gemcitabine Plus Cisplatin for Patients With First-Line Advanced Biliary Tract Cancers

NCT07710885 is registered in ClinicalTrials.gov with Taiho Pharmaceutical Co., Ltd. as lead sponsor.

NCT NCT07710885
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07710885 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 3, Randomized-Controlled, Open-Label, Multi-Regional, International Study of Futibatinib (TAS-120) and Zimberelimab (AB122) in Combination With Gemcitabine Plus Cisplatin Versus Durvalumab or Pembrolizumab in Combination With Gemcitabine Plus Cisplatin for Patients With First-Line Advanced Biliary Tract Cancers
Lead sponsor
Taiho Pharmaceutical Co., Ltd.
Phase
Phase 3
Overall status
Recruiting
Start date
June 24, 2026
Completion date
December 31, 2031
Enrollment
784 (estimated)
Sites
21

Conditions

As the registry lists them; a condition with its own page is linked.

biliary tract cancer